Insider Transactions in Q2 2023 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2023
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,136
-4.09%
|
$10,224
$9.88 P/Share
|
|
May 01
2023
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
682
-6.36%
|
$6,138
$9.88 P/Share
|
|
May 01
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
721
-0.91%
|
$6,489
$9.88 P/Share
|
|
May 01
2023
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
342
-5.3%
|
$3,078
$9.88 P/Share
|
|
Apr 30
2023
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,206
+10.35%
|
-
|
|
Apr 30
2023
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+15.21%
|
-
|
|
Apr 30
2023
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+3.5%
|
-
|
|
Apr 30
2023
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+12.97%
|
-
|